YOLFTbeta
Exact Therapeutics AS

Exact Therapeutics AS

EXTX · OL · Healthcare / Biotechnology

0.70NOK-0.09 (-11.39%)

Price History

Full chart

Market Stats

Previous Close0.79
Open0.426
Day Range0.426 – 0.70
52-Week Range0.58 – 2.70
Volume400.46K
Market Cap75.29M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.93
Dividend Yield0.00%
Beta0.09
50-Day Avg0.7356
200-Day Avg1.28

About

EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a novel ultrasound-mediated technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT) in Norway. The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various applications, including oncology, neurological conditions, and gene therapy. The company's ACT platform is under Phase 2 clinical trial for the treatment of pancreatic disease; Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for glioblastoma, and immunotherapy diseases, as well as CNS diseases and gene therapy. It has a collaboration with GE Healthcare. The company was formerly known as Phoenix Solutions AS. EXACT Therapeutics AS was founded in 2012 and is based in Oslo, Norway.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Per Edvard Walday Ph.D.
  • Employees11
  • HeadquartersØstre Aker vei 19, Oslo, Norway, 0581, Norway
  • Websitehttps://exact-tx.com

Leadership

  • Dr. Per Edvard Walday Ph.D.Chief Executive Officer · b. 1960
  • Dr. Svein KvåleCo-Founder & COO
  • Mr. John M. EdminsonChief Financial Officer
  • Dr. Masha Paule Nathalie Legris Stromme DPHILDirector
  • Dr. Amir Snapir M.D., Ph.D.Chief Medical Officer · b. 1961
  • Mr. Caspar FoghsgaardChief Business Officer
  • Dr. Per Christian SontumFounder
  • Mr. Ragnar BendicksenVice President of Technology

Financials

Income Statement

Currency: NOK2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0088.25K000000
Growth (%)----100.00%-----
Operating Income-4.95M-7.62M-15.98M-34.70M-59.11M-40.77M-48.38M-52.85M-84.88M
Operating Margin---18112.43%------
EBITDA--7.45M-14.63M-31.98M-56.66M-38.46M-46.20M-49.85M-83.25M
EBITDA Margin---16574.15%------
Net Income-4.91M-7.59M-14.82M-33.09M-58.59M-40.10M-48.33M-52.33M-86.97M
Net Income Margin---16799.67%------
R&D---13.31M34.49M19.91M19.74M25.21M40.54M
Interest Expense07.71K71.87K23.62K100.11K98.93K85.64K54.46K34.89K
Interest Expense % of Total Revenue--81.44%------

Balance Sheet

Currency: NOK2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets20.02M63.23M52.10M170.23M117.63M82.51M61.32M153.20M67.40M
Total Liabilities11.68M6.17M9.87M10.58M11.89M17.40M16.22M37.65M36.69M
Total Equity8.35M57.06M42.24M159.65M105.74M65.11M45.10M115.55M30.71M
Cash15.15M58.67M23.23M138.92M82.46M68.50M45.57M98.02M23.47M

Cash Flow

Currency: NOK2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-12.46M-12.46M-12.46M-25.99M-55.11M-33.85M-44.30M-80.55M-66.99M
Investing Cash Flow-23.03M-23.03M-23.03M-980.87K-1.01M20.60M-2.15M-580.74K-
Financing Cash Flow-114.23K-114.23K-114.23K142.57M-47.39K-530.69K23.17M134.33M-
Capital Expenditure1.40M1.40M1.40M3.96M1.63M250.98K3.09M1.51M5.32M
Free Cash Flow--12.25M-13.82M-29.95M-56.74M-34.10M-47.39M-82.05M-72.31M
FCF to OCF-98.24%110.88%115.25%102.95%100.74%106.98%101.87%107.94%

Key Statistics & Ratios

Market Cap75.29M
Enterprise Value40.51M
Trailing P/E0.00
Forward P/E0.00
Price / Sales965.29
Price / Book1.35
EPS-0.93
Book Value1.04
Revenue (TTM)78.00K
Gross Profit (TTM)78.00K
EBITDA-74.01M
Profit Margin0.00%
Operating Margin-199799.21%
Return on Equity-113.46%
Return on Assets-51.64%
Shares Outstanding111.54M
Shares Float62.69M
Beta0.09
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jul 27, 2020250:1